| First Author | Yang J | Year | 2016 |
| Journal | Nat Commun | Volume | 7 |
| Pages | 13710 | PubMed ID | 27966531 |
| Mgi Jnum | J:243232 | Mgi Id | MGI:5907946 |
| Doi | 10.1038/ncomms13710 | Citation | Yang J, et al. (2016) Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment. Nat Commun 7:13710 |
| abstractText | Interstitial fibrosis plays a key role in the development and progression of heart failure. Here, we show that an enzyme that crosslinks collagen-Lysyl oxidase-like 2 (Loxl2)-is essential for interstitial fibrosis and mechanical dysfunction of pathologically stressed hearts. In mice, cardiac stress activates fibroblasts to express and secrete Loxl2 into the interstitium, triggering fibrosis, systolic and diastolic dysfunction of stressed hearts. Antibody-mediated inhibition or genetic disruption of Loxl2 greatly reduces stress-induced cardiac fibrosis and chamber dilatation, improving systolic and diastolic functions. Loxl2 stimulates cardiac fibroblasts through PI3K/AKT to produce TGF-beta2, promoting fibroblast-to-myofibroblast transformation; Loxl2 also acts downstream of TGF-beta2 to stimulate myofibroblast migration. In diseased human hearts, LOXL2 is upregulated in cardiac interstitium; its levels correlate with collagen crosslinking and cardiac dysfunction. LOXL2 is also elevated in the serum of heart failure (HF) patients, correlating with other HF biomarkers, suggesting a conserved LOXL2-mediated mechanism of human HF. |
